SHIONOGI & CO., LTD. Ping An Insurance (Group) Company of China, Ltd. announced that Ping An-Shionogi Co., Ltd. (Ping An-Shionogi), a joint venture between Ping An and Shionogi & Co., Ltd., has been launched in Shanghai. Ping An-Shionogi is a Healthcare as a Service (HaaS) enterprise, an integrated medical and healthcare platform, for public health and patients. The joint venture is a collaboration between the Ping An and Shionogi in drug research, development, production and sales.
It is based on Ping An's sophisticated healthcare ecosystem and advanced digital technology and Shionogi's strengths in drug research and development. Using Ping An's leading healthtech capabilities, resources and advantages in insurance and financial services, and Shionogi's drug development capability and experience in the pharmaceutical industry, Ping An-Shionogi is committed to providing customers with personalized health management solutions, including exercise suggestions, medical prescriptions on over-the-counter drugs, vaccines, new drugs for different stages of healthcare including disease prevention, diagnosis, medical prescription and follow-up visits. It will create a new benchmark for the healthcare industry.
Ping An's strong digital capability is enabling Ping An-Shionogi to speed up drug development with data for specific diseases. It also uses Shionogi's pharmaceutical research center to explore new drugs and conduct drug research and development in a more efficient and effective way. Ping An-Shionogi will also draw on Ping An's abundant medical resources to explore a new rapid clinical trial enrollment model to promote Shionogi's development of new drugs in China.
Two new types of drugs developed by Shionogi are being promoted according to the plan. In terms of production, Ping An-Shionogi will build a new drug production system and implement the first digital management mechanism for pharmaceutical manufacturing in China. It will automate instructions and maintain digital records in the pharmaceutical production process and speed up drug development to enhance the quality and efficiency of medical and healthcare services.
